About: Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany
Creator	Drosten, Christian Corman, Victor De Vries, M Schmidt, Marie Thomas, ; Schmidt, H Antje, ; Breteler, Monique Richter, Anja Ahmad Aziz, Authors Echterhoff, K Folgerdiena, ; Schmandke, ;
Source	MedRxiv
abstract	Background Accurate estimates of SARS-CoV-2 seroprevalence are crucial for the implementation of effective public health measures, but are currently largely lacking in regions with low infection rates. This is further complicated by inadequate test performance of many widely used serological assays. We therefore aimed to assess SARS-CoV-2 seroprevalence in a region with low COVID-19 burden, especially focusing on neutralizing antibodies that presumably constitute a major component of acquired immunity. Methods We invited all individuals who were enrolled in the Rhineland Study, an ongoing community-based prospective cohort study in people aged 30 years and above in the city of Bonn, Germany (N=5427). Between April 24th and June 30th, 2020, 4771 (88%) of these individuals participated in the serosurvey. Anti-SARS-CoV-2 IgG levels were measured using an ELISA assay, and all positive or borderline results were subsequently examined through both a recombinant immunofluorescent assay and a plaque reduction neutralisation test (PRNT). Findings Seroprevalence was 0.97% (95% CI: 0.72-1.30) by ELISA and 0.36% (95% CI: 0.21-0.61) by PRNT, and did not vary with either age or sex. All PRNT+ individuals reported having experienced at least one symptom (odds ratio (OR) of PRNT+ for each additional symptom: 1.12 (95% CI: 1.04-1.21)). Apart from living in a household with a SARS-CoV-2 confirmed or suspected person, a recent history of reduced taste or smell, fever, chills/hot flashes, pain while breathing, pain in arms/legs, as well as muscle pain and weakness were significantly associated with the presence of neutralizing antibodies in those with mild to moderate infection (ORs 3.44 to 9.97, all p<0.018). Interpretation Our findings indicate a relatively low SARS-CoV-2 seroprevalence in Bonn, Germany (until June 30th, 2020), with neutralizing antibodies detectable in only one third of those with a positive immunoassay result, implying that almost the entire population in this region remains susceptible to SARS-CoV-2 infection.
has issue date	2020-08-29(xsd:dateTime)
bibo:doi	10.1101/2020.08.24.20181206
has license	medrxiv
sha1sum (hex)	9f6d8d6300049677317132dc63989140929200f7
schema:url	https://doi.org/10.1101/2020.08.24.20181206
resource representing a document's title	Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany
resource representing a document's body	covid:9f6d8d6300049677317132dc63989140929200f7#body_text
is schema:about of	named entity 'SARS-CoV-2' named entity 'immunoassay' named entity 'SARS-CoV-2' named entity 'social distancing' named entity 'Gaussian' named entity 'follow-up' named entity 'odds ratio' named entity 'Fisher's exact test' named entity 'vaccination' named entity 'neutralizing antibodies' named entity 'muscle weakness' named entity 'seroprevalence' named entity 'neutralizing antibodies' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'Bonn' named entity 'IgG' named entity 'acute infection' named entity 'peer review' named entity 'preprint' named entity 'PRNT' named entity 'Bonn' named entity 'Germany' named entity 'seropositivity' named entity 'body mass index' named entity 'clinical characteristics' named entity 'preprint' named entity 'serosurvey' named entity 'selection bias' named entity 'Germany' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'immunoassay' named entity 'peer review' named entity 'confidence intervals' named entity 'seizures' named entity 'cellular immunity' named entity 'preprint' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'comorbidities' named entity 'Fisher's exact test' named entity 'IgG antibodies' named entity 'neutralizing antibody' named entity 'fever' named entity 'odds ratios' named entity 'sequelae' named entity 'neutralizing antibodies' named entity 'neutralizing antibodies' named entity 'infection' named entity '95% CI' named entity 'IgG' named entity 'T-cells' named entity 'antibodies' named entity 'neutralizing antibodies' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'ELISA assay' named entity 'infection' named entity 'population immunity' named entity 'neutralizing antibodies' named entity 'link function' named entity 'SARS-CoV-2' named entity 'follow-up' named entity 'SARS-CoV-2' named entity 'odds ratio' named entity 'Rhineland' named entity 'asymptomatic' named entity 'morbidity' named entity 'statistical significance' named entity 'hot flashes'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software